BOSTON--(BUSINESS WIRE)--Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors. Mr. Wyzga brings over two decades of deep experience leading and advising life sciences companies to the Glyscend Board.
'As we continue to progress our lead asset, GLY-200, through clinical development, his broad experience in leadership roles across the areas of finance, strategic planning and corporate development will be invaluable. I, along with the rest of the Board, look forward to his partnership.'
“We are thrilled to welcome Mike, a distinguished biotech industry expert, to the Glyscend team,” said Ashish Nimgaonkar, M.D., President and CEO of Glyscend. “As we continue to progress our lead asset, GLY-200, through clinical development, his broad experience in leadership roles across the areas of finance, strategic planning and corporate development will be invaluable. I, along with the rest of the Board, look forward to his partnership.”
Mr. Wyzga added, “I’m pleased to join the Glyscend Board of Directors during this exciting time for the company. With encouraging findings observed with GLY-200 in Glyscend’s Phase 1 trial, I believe this drug, with its unique, gut-targeted approach, could provide a promising option to help patients achieve glycemic and bodyweight control in a highly convenient and safe manner. I look forward to working with Glyscend’s expert management team as the company continues to develop an innovative treatment option for Type 2 diabetes and obesity.”
Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally administered, polymer therapies that work on targets inside the gastrointestinal tract to treat a variety of metabolic and chronic disorders. Polymer-based therapies are a unique class of therapeutics with more than three decades of clinical experience in a wide range of applications. Glyscend’s polymer technology platform evolved out of research at Johns Hopkins University where scientists were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation that precedes weight loss in certain types of metabolic surgery. The company’s lead product candidate, GLY-200, is in clinical development initially for the treatment of Type 2 diabetes and/or obesity. In addition, Glyscend is exploring new program opportunities that address topical GI as well as systemic, inflammatory, and autoimmune conditions. The company is also investigating use of its technology platform to unlock novel GI tract targets using polymer-drug conjugates and to enhance the oral bioavailability of peptide therapies. For more information, please visit www.glyscend.com.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.